A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Clinical trial NCT03693300 · COMPLETED

Trial details

NCT number: NCT03693300
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer (NSCLC)

Start date: 2019-04-16
Primary completion: 2022-12-13
Enrollment: 117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.